First presentation of full preclinical profile of KRLS-017, a potentially best in class reversible small molecule inhibitor of Cyclin Dependent Kinase 7 (CDK7) San Francisco,

Phase 1 clinical study will evaluate the safety, pharmacokinetics, and preliminary efficacy of KRLS-017 in treatment refractory solid tumors San Francisco, CA, April 28, 2023

Ongoing Phase 1 clinical study is evaluating the safety, pharmacokinetics, and preliminary efficacy of ASN-004 in treatment refractory solid tumors San Francisco, CA, September 1,

Kirilys Therapeutics, Inc., a private, preclinical-stage biopharmaceutical company founded by investment firm Catalys Pacific, announced today that the Company completed a seed financing led by Lightspeed Venture Partners.